News

Stephan Moll, MD, professor of medicine and member of the UNC Hemophilia and Thrombosis Center, co-authored the results of a large-scale multicenter clinical trial focusing on catheter-directed thrombolysis and its effects.

In August 2017, Pfizer committed to building a $100 million gene therapies plant in North Carolina and, in exchange, North Carolina committed to providing the drugmaker with a quarter-million dollars' worth of help.
Pfizer will expand an 11,000-square-foot plant in Sanford, North Carolina that it acquired last year when it bought gene therapies biotech Bamboo Therapeutics in a deal valued at up to $688 million. Bamboo bought the facility last year from the University of North Carolina about the time that Pfizer made its initial investment in the company.

UNC Hemophilia Treatment Center physical therapist Jennifer Newman, PT, MSPT, will moderate and speak at sessions on August 24, 2017 and August 25, 2017 at the National Hemophilia Foundation annual meeting in Chicago.

The HHT International Scientific Conference is held every other year. It is the premier conference on HHT, and over 250 basic and clinical researchers from around the world attend and present their work. The 12th HHT International Scientific Conference was held from June 8-11, 2017 in Dubrovnik.

Dr. Nigel Key, Professor of Medicine and Pathology, Chief of the Section of Classical Hematology, and the Director of the UNC Hemophilia and Thrombosis Center, was a keynote speaker at the annual Earl W. Davie Symposium in Vancouver, BC on November 17, 2016.

The International Society on Thrombosis and Hemostasis will hold its Advanced Training Course in Thrombosis and Hemostasis in Atlanta, Georgia, November 1-4, 2016. UNC Hemophilia and Thrombosis Center Director Nigel Key, M.D., is chairing and speaking, and UNC physician Stephan Moll, M.D., is speaking as well.

"Endeavors" magazine, which writes about research and creative activity at UNC-Chapel Hill, published an article in its July issue about UNC-Chapel Hill's history of research and treatment for blood disorders, which began in 1947 under Dr. Kenneth Brinkhous. His seminal work set the stage for major breakthroughs in hemophilia and HIV.

George McCoy, a longtime patient at the UNC Hemophilia & Thrombosis Center and the first man in the world to receive recombinant clotting factor, was the subject of a news story on WTVD on February 16.

UNC's 340B pharmacy's accreditation by URAC became effective February 1, 2016. URAC's mission is to promote continuous improvement in the quality and efficiency of health care management through processes of accreditation, education, and measurement.

In a press release dated January 19, 2016, the International Society on Thrombosis and Haemostasis (ISTH) announced its new international clinical Core Curriculum on thrombosis and hemostasis, the first framework of its kind to define the minimum standards for a medical doctor to attain a level of proficiency to enable them to practice independently as specialists in the field.